Source: Thailand Medical News  Dec 06, 2019  5 years, 10 months, 4 weeks, 1 day, 1 hour, 28 minutes ago
                            
                                        
                            According to a study published in 
JAMA Network Open, 
Aspirin use three or more times per week is associated with reductions in all-cause, any 
cancer, gastrointestinal 
cancer, and colorectal 
cancer (CRC) mortality among older adults.
Dr Holli A. Loomans-Kropp, Ph.D., M.P.H., from the National 
Cancer Institute in Rockville, Maryland, and colleagues examined the correlation of aspirin use with all-cause, any 
cancer, gastrointestinal, and CRC mortality among 146,152 individuals (mean age at baseline, 66.3 years) who were followed for a median of 12.5 years encompassing 1,822,164 person-years.
The medical researchers found that 
aspirin use one to three times per month correlated with a reduced risk for all-cause and 
cancer mortality compared with no use (hazard ratios, 0.84 and 0.87, respectively). Reduced risks for mortality of all causes, any cancer, gastrointestinal 
cancer, and CRC were seen with aspirin use three or more times per week (hazard ratios, 0.81, 0.85, 0.75, and 0.71, respectively). On stratification by body mass index (BMI), aspirin use three or more times per week correlated with a reduced risk for all-cause and any 
cancer mortality among those with a BMI of 20 to 24 kg/m² (hazard ratios, 0.82 and 0.86, respectively) and with reduced risk for all-cause, any 
cancer, gastrointestinal 
cancer, and CRC mortality with a BMI of 25 to 29.9 kg/m² (hazard ratios, 0.82, 0.86, 0.72, and 0.66, respectively).
Dr Holli A. Loomans-Kropp told 
Thailand Medical News, "Future studies should further examine the association of BMI with the efficacy of 
aspirin as a 
cancer preventive agent to adapt to the changing global obesity trends."
One author disclosed financial ties to the pharmaceutical industry.
Reference: Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, Holli A. Loomans-Kropp, PhD, MPH1,2; Paul Pinsky, PhD3; Yin Cao, ScD, MPH4; et alAndrew T. Chan, MD, MPH5,6,7,8; Asad Umar, PhD, DVM2 JAMA Netw Open. 2019;2(12):e1916729. doi:10.1001/jamanetworkopen.2019.16729